Kuehnelt Doris, Kienzl Norbert, Traar Pedro, Le Nam Hoang, Francesconi Kevin A, Ochi Takafumi
Institute of Chemistry-Analytical Chemistry, Karl-Franzens University Graz, Universitaetsplatz 1, 8010, Graz, Austria.
Anal Bioanal Chem. 2005 Sep;383(2):235-46. doi: 10.1007/s00216-005-0007-8. Epub 2005 Oct 12.
To obtain quantitative information on human metabolism of selenium, we have performed selenium speciation analysis by HPLC/ICPMS on samples of human urine from one volunteer over a 48-hour period after ingestion of selenium (1.0 mg) as sodium selenite, L-selenomethionine, or DL-selenomethionine. The three separate experiments were performed in duplicate. Normal background urine from the volunteer contained total selenium concentrations of 8-30 microg Se/L (n=22) but, depending on the chromatographic conditions, only about 30-70% could be quantified by HPLC/ICPMS. The major species in background urine were two selenosugars, namely methyl-2-acetamido-2-deoxy-1-seleno-beta-D-galactopyranoside (selenosugar 1) and its deacylated analog methyl-2-amino-2-deoxy-1-seleno-beta-D-galactopyranoside (selenosugar 3). Selenium was rapidly excreted after ingestion of the selenium compounds: the peak concentrations (approximately 250-400 microg Se/L, normalized concentrations) were recorded within 5-9 hours, and concentrations had returned to close to background levels within 48 hours, by which time 25-40% of the ingested selenium, depending on the species ingested, had been accounted for in the urine. In all experiments, the major metabolite was selenosugar 1, constituting either approximately 80% of the total selenium excreted over the first 24 hours after ingestion of selenite or L-selenomethionine or approximately 65% after ingestion of DL-selenomethionine. Selenite was not present at significant levels (<1 microg Se/L) in any of the samples; selenomethionine was present in only trace amounts (approximately 1 microg/L, equivalent to less than 0.5% of the total Se) following ingestion of L-selenomethionine, but it constituted about 20% of the excreted selenium (first 24 hours) after ingestion of DL-selenomethionine, presumably because the D form was not efficiently metabolized. Trimethylselenonium ion, a commonly reported urine metabolite, could not be detected (<1 microg/L) in the urine samples after ingestion of selenite or selenomethionine. Cytotoxicity studies on selenosugar 1 and its glucosamine isomer (selenosugar 2, methyl-2-acetamido-2-deoxy-1-seleno-beta-D-glucosopyranoside) were performed with HepG2 cells derived from human hepatocarcinoma, and these showed that both compounds had low toxicity (about 1000-fold less toxic than sodium selenite). The results support earlier studies showing that selenosugar 1 is the major urinary metabolite after increased selenium intake, and they suggest that previously accepted pathways for human metabolism of selenium involving trimethylselenonium ion as the excretionary end product may need to be re-evaluated.
为获取有关人体硒代谢的定量信息,我们在一名志愿者摄入亚硒酸钠、L-硒代蛋氨酸或DL-硒代蛋氨酸形式的硒(1.0毫克)后的48小时内,通过HPLC/ICPMS对其尿液样本进行了硒形态分析。这三项独立实验均重复进行。该志愿者的正常背景尿液中总硒浓度为8 - 30微克硒/升(n = 22),但根据色谱条件,通过HPLC/ICPMS仅能定量约30 - 70%的硒。背景尿液中的主要成分是两种硒糖,即甲基-2-乙酰氨基-2-脱氧-1-硒代-β-D-吡喃半乳糖苷(硒糖1)及其脱酰基类似物甲基-2-氨基-2-脱氧-1-硒代-β-D-吡喃半乳糖苷(硒糖3)。摄入硒化合物后,硒迅速排出:在5 - 9小时内记录到峰值浓度(约250 - 400微克硒/升,归一化浓度),48小时内浓度已恢复至接近背景水平,此时根据摄入的硒种类不同,尿液中已排出摄入硒的25 - 40%。在所有实验中,主要代谢产物都是硒糖1,在摄入亚硒酸钠或L-硒代蛋氨酸后的前24小时内,它约占总排出硒的80%,而在摄入DL-硒代蛋氨酸后约占65%。在任何样本中,亚硒酸盐含量均不显著(<1微克硒/升);摄入L-硒代蛋氨酸后,硒代蛋氨酸仅以痕量存在(约1微克/升,相当于总硒的不到0.5%),但在摄入DL-硒代蛋氨酸后,它约占排出硒的20%(前24小时),推测是因为D型不能有效代谢。在摄入亚硒酸盐或硒代蛋氨酸后的尿液样本中未检测到常见报道的尿液代谢产物三甲基硒离子(<1微克/升)。对源自人肝癌的HepG2细胞进行了硒糖1及其葡糖胺异构体(硒糖2,甲基-2-乙酰氨基-2-脱氧-1-硒代-β-D-吡喃葡萄糖苷)的细胞毒性研究,结果表明这两种化合物毒性都很低(毒性比亚硒酸钠小约1000倍)。这些结果支持了早期研究,即表明硒糖1是硒摄入量增加后的主要尿液代谢产物,并且表明之前公认的以三甲基硒离子作为排泄终产物的人体硒代谢途径可能需要重新评估。